Charles River Laboratories Intl. Inc vs Opendoor Technologies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $284.26 (market cap $13.46B), while Opendoor Technologies Inc trades at $3.52 (market cap $3.45B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.9× Opendoor Technologies Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.
| CRL | OPEN | |
|---|---|---|
Market Cap | $13.46B | $3.45B |
Sector | Health | Real Estate |
52-Week High | $282.00 | $10.52 |
52-Week Low | $145.57 | $2.42 |
Enterprise Value | $16.30B | $4.52B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Opendoor Technologies (OPEN) trades at $3.48, down 0.29% today, reflecting ongoing challenges in the housing market. The stock shows bearish technical signals with mixed earnings performance - beating Q4 2025 estimates but missing Q1 and Q2 2026 expectations. Revenue has declined from $15.6B in 2022 to $4.4B in 2025, with net losses widening to $1.3B last year. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $3.58 offers modest upside potential.
The outlook remains challenging as high interest rates and housing market weakness pressure Opendoor's iBuying model. While the company maintains strong cash flow from operations ($1.05B in 2025) and trades below book value, persistent losses and competitive threats from Zillow create significant headwinds. Investors should weigh the company's market position against ongoing profitability concerns in a difficult real estate environment.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →